SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Viable Monetary Tips to Advance Your Monetary Circumstance - 2The Most Compelling Innovation Advancements Somewhat recently
- 3Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- 44 Home Rec center Hardware Decisions for Little Spaces
- 5Foreign journalist kidnapped in Iraq: Interior Ministry
- Asia's migrant workers debate if Gulf jobs are worth deadly risk of Iran war
- Building a Maintainable Closet: Individual Excursions in Moral Style
- Conquering Language Boundaries: Individual Accounts of Multilingualism
- Rights groups condemn Israel Police decision to ban Sudan Genocide protests nationwide
- The Best Computer games Ever
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- 'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
- I read 115 books this year. 'Wuthering Heights,' 'Heart the Lover' and 'The House of My Mother' were among my 10 favorites.
- A red meat allergy from tick bites is spreading – and the lone star tick isn’t the only alpha-gal carrier to worry about
